Astellas Pharma Owners | StatInvestor

Health Care & Life Sciences » Pharmaceuticals | Astellas Pharma Inc.

Astellas Pharma Inc. | Ownership

Companies that own Astellas Pharma Inc.

Name

Shares Held

% Shares Out

Change In Shares

% of Assets

As of Date

Nomura Asset Management Co., Ltd.

99,097,500

5.01%

28,364,500

0.95%

07/13/2018

BlackRock Fund Advisors

80,638,551

4.07%

6,558,000

0.07%

06/15/2017

Nikko Asset Management Co., Ltd.

56,630,900

2.86%

18,153,700

0.56%

03/30/2018

BlackRock Japan Co., Ltd.

52,512,300

2.65%

8,917,600

1.14%

06/15/2017

The Vanguard Group, Inc.

48,851,124

2.47%

388,092

0.03%

07/31/2018

Daiwa Asset Management Co. Ltd.

42,506,395

2.15%

227,896

0.82%

07/31/2018

Norges Bank Investment Management

29,633,632

1.5%

421,659

0.07%

12/31/2017

International Value Advisers LLC

29,017,000

1.47%

-7,059,300

5.18%

03/31/2018

Wellington Management Co. LLP

26,806,900

1.35%

-5,969,810

0.09%

06/30/2018

First Eagle Investment Management LLC

24,355,050

1.23%

-2,948,226

0.54%

04/30/2018

About Astellas Pharma

View Profile

Address	2-5-1 Nihonbashi-Honcho Tokyo Tokyo 103 Japan
Employees	-
Website	http://www.astellas.com
Updated	07/08/2019
Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. Its products focus on therapeutic fields that include transplantation, immunology, infectious diseases, urology, oncology, neuroscience, diabetic complications, and metabolic diseases. The firm's global brands include Prograf, Vesicare, Protopic, Harnal, and Funguard.